Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma.
- Author:
Sen WU
1
;
Ming-yao CHEN
;
Jian-chao LUO
;
Li WEI
;
Zhong CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Carcinoma, Squamous Cell; pathology; surgery; therapy; Chemoradiotherapy; Cisplatin; administration & dosage; adverse effects; Esophageal Neoplasms; pathology; surgery; therapy; Female; Fluorouracil; administration & dosage; adverse effects; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; chemically induced; Radiotherapy, High-Energy; Remission Induction; Taxoids; administration & dosage; adverse effects; Vomiting; chemically induced
- From: Chinese Journal of Oncology 2012;34(11):873-876
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the efficacy and feasibility of neoadjuvant chemoradiotherapy with docetaxel plus cisplatin or with cisplatin plus fluorouracil in the treatment of local advanced esophageal squamous cell carcinoma.
METHODSA total of 154 cases in the stage of cT3N0-1M0 were randomly assigned to two arms. The arm A received 2 cycles of doctaxel 75 mg/m(2) plus cisplatin 25 mg/m(2) d1-3 and 40 Gy of radiation therapy, and the arm B received 2 cycles of cisplatin 25 mg/m(2) d1-3 plus fluorouracil 600 mg/m(2) d1 ∼ 5 and 40 Gy of radiation therapy. The surgery was performed 3 - 4 weeks later.
RESULTSGrade 3/4 toxicities occurred in 53.2% of the patients in arm A and in 36.4% of the patients in arm B (P = 0.035). Neutropenia occurred in 20.7% of the patients in arm A and 5.6% of the patients in arm B (P = 0.004). Nine patients aborted surgery due to tumor progression. 71 patients underwent resection in 73 cases of the arm A and 69 patients underwent complete resection, 70 patients underwent resection in 72 cases and 70 complete resection of the arm B, respectively (P > 0.05). No mortality was noted. The overall complication rate was similar in the two arms (21.9% vs. 23.6%). Pathological complete response was achieved in 27 patients (35.1%) in the arm A and 16 patients (20.8%) in the arm B (P = 0.048).
CONCLUSIONSNeoadjuvant chemoradiotherapy with docetaxel plus cisplatin can be well tolerated and achieves a higher pathological complete response rate than with cisplatin plus fluorouracil.
